2024年12月18日 · PG3 has the potential to revolutionize cancer treatment by overcoming the resistance of p53-deficient tumors to existing therapies. By restoring critical tumor-suppressing signals in cancer cells that are otherwise resistant, PG3 offers a new approach to treating some of the most aggressive and challenging cancers.

2024年8月8日 · Intravenous immunoglobulin (IVIG) was found to be an effective and safe treatment for patients with pyoderma gangrenosum (PG), with a particular role noted for patients who are poor candidates for immunosuppression treatment, according to a systematic review published in the Journal of the European Academy of Dermatology and Venereology.1

2012年11月13日 · Phosphoglycerate mutase 1 (PGAM1) catalyzes the conversion of 3-phosphoglycerate (3-PG) to 2-phosphoglycerate (2-PG) during glycolysis. PGAM1 regulates a unique step in glycolysis, and most of the glycolytic intermediates that are used as precursors for anabolic biosynthesis are upstream of this step.

Phosphoglycerate mutase 1 (PGAM1) catalyzes the conversion of 3-phosphoglycerate (3-PG) to 2-phosphoglycerate (2-PG) during glycolysis. PGAM1 regulates a unique step in glycolysis, and most of the glycolytic intermediates that are used as precursors for anabolic biosynthesis are upstream of this step.

2022年9月19日 · Targeting the serine biosynthesis pathway enzymes has turned up as a novel strategy for anti-cancer therapeutics. 3- Phosphoglycerate dehydrogenase (PHGDH) is the rate-limiting enzyme that catalyzes the conversion of 3-Phosphoglyceric acid (3-PG) into 3-Phosphohydroxy pyruvate (3-PPyr) in the first step of serine synthesis pathway and perform a ...

This review demonstrates a growing number of reports where use of IL-23 inhibitors was beneficial in treatment of refractory PG. IL-23 inhibitors may be a relatively safe and effective treatment for PG and should be further explored in prospective controlled studies.

Systemic therapy with corticosteroids and/or cyclosporine remains the treatment of choice for most patients with pyoderma gangrenosum. Based on new data, systemic therapies with biologics are gaining importance as alternative or first-line therapy in …

2023年8月23日 · Systemic therapy with corticosteroids and/or cyclosporine remains the treatment of choice for most patients with pyoderma gangrenosum. Based on new data, systemic therapies with biologics are gaining importance as alternative or first-line therapy in patients with inflammatory comorbidities.

2022年9月19日 · Targeting the serine biosynthesis pathway enzymes has turned up as a novel strategy for anti-cancer therapeutics. 3- Phosphoglycerate dehydrogenase (PHGDH) is the rate-limiting enzyme that catalyzes the conversion of 3-Phosphoglyceric acid (3-PG) into 3-Phosphohydroxy pyruvate (3-PPyr) in the first …

2025年2月24日 · This randomized clinical trial evaluates the efficacy of sugemalimab plus capecitabine and oxaliplatin (CAPOX) vs placebo plus CAPOX as first-line treatment for unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma with programmed death-ligand 1 combined...